The hemostatic role of factor XI

Cristina Puy, Rachel A. Rigg, Owen McCarty

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Coagulation factor (F)XI has been described as a component of the early phase of the contact pathway of blood coagulation, acting downstream of factor XII. However, patients deficient in upstream members of the contact pathway, including FXII and prekallikrein, do not exhibit bleeding complications, while FXI-deficient patients sometimes experience mild bleeding, suggesting FXI plays a role in hemostasis independent of the contact pathway. Further complicating the picture, bleeding risk in FXI-deficient patients is difficult to predict because bleeding symptoms have not been found to correlate with FXI antigen levels or activity. However, recent studies have emerged to expand our understanding of FXI, demonstrating that activated FXI is able to activate coagulation factors FX, FV, and FVIII, and inhibit the anti-coagulant tissue factor pathway inhibitor (TFPI). Understanding these activities of FXI may help to better diagnose which FXI-deficient patients are at risk for bleeding. In contrast to its mild hemostatic activities, FXI is known to play a significant role in thrombosis, as it is a demonstrated independent risk factor for deep vein thrombosis, ischemic stroke, and myocardial infarction. Recent translational approaches have begun testing FXI as an antithrombotic, with one promising clinical study showing that an anti-sense oligonucleotide against FXI prevented venous thrombosis in elective knee surgery. A better understanding of the varied and complex role of FXI in both thrombosis and hemostasis will help to allow better prediction of bleeding risk in FXI-deficient patients and also informing the development of targeted agents to inhibit the thrombotic activities of FXI while preserving hemostasis.

Original languageEnglish (US)
Pages (from-to)S8-S11
JournalThrombosis Research
Volume141
DOIs
StatePublished - May 1 2016

Fingerprint

Factor XI
Hemostatics
Hemorrhage
Hemostasis
Venous Thrombosis
Thrombosis
Prekallikrein
Factor XII
Coagulants
Blood Coagulation Factors
Antisense Oligonucleotides
Blood Coagulation
Knee
Stroke
Myocardial Infarction
Antigens

Keywords

  • bleeding
  • coagulation factor XI
  • coagulation factor XII
  • contact activation pathway
  • hemophilia C
  • hemostasis

ASJC Scopus subject areas

  • Hematology

Cite this

The hemostatic role of factor XI. / Puy, Cristina; Rigg, Rachel A.; McCarty, Owen.

In: Thrombosis Research, Vol. 141, 01.05.2016, p. S8-S11.

Research output: Contribution to journalArticle

Puy, Cristina ; Rigg, Rachel A. ; McCarty, Owen. / The hemostatic role of factor XI. In: Thrombosis Research. 2016 ; Vol. 141. pp. S8-S11.
@article{3a6c7950a9ab4ffeb9b8c2724dd433ba,
title = "The hemostatic role of factor XI",
abstract = "Coagulation factor (F)XI has been described as a component of the early phase of the contact pathway of blood coagulation, acting downstream of factor XII. However, patients deficient in upstream members of the contact pathway, including FXII and prekallikrein, do not exhibit bleeding complications, while FXI-deficient patients sometimes experience mild bleeding, suggesting FXI plays a role in hemostasis independent of the contact pathway. Further complicating the picture, bleeding risk in FXI-deficient patients is difficult to predict because bleeding symptoms have not been found to correlate with FXI antigen levels or activity. However, recent studies have emerged to expand our understanding of FXI, demonstrating that activated FXI is able to activate coagulation factors FX, FV, and FVIII, and inhibit the anti-coagulant tissue factor pathway inhibitor (TFPI). Understanding these activities of FXI may help to better diagnose which FXI-deficient patients are at risk for bleeding. In contrast to its mild hemostatic activities, FXI is known to play a significant role in thrombosis, as it is a demonstrated independent risk factor for deep vein thrombosis, ischemic stroke, and myocardial infarction. Recent translational approaches have begun testing FXI as an antithrombotic, with one promising clinical study showing that an anti-sense oligonucleotide against FXI prevented venous thrombosis in elective knee surgery. A better understanding of the varied and complex role of FXI in both thrombosis and hemostasis will help to allow better prediction of bleeding risk in FXI-deficient patients and also informing the development of targeted agents to inhibit the thrombotic activities of FXI while preserving hemostasis.",
keywords = "bleeding, coagulation factor XI, coagulation factor XII, contact activation pathway, hemophilia C, hemostasis",
author = "Cristina Puy and Rigg, {Rachel A.} and Owen McCarty",
year = "2016",
month = "5",
day = "1",
doi = "10.1016/S0049-3848(16)30354-1",
language = "English (US)",
volume = "141",
pages = "S8--S11",
journal = "Thrombosis Research",
issn = "0049-3848",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - The hemostatic role of factor XI

AU - Puy, Cristina

AU - Rigg, Rachel A.

AU - McCarty, Owen

PY - 2016/5/1

Y1 - 2016/5/1

N2 - Coagulation factor (F)XI has been described as a component of the early phase of the contact pathway of blood coagulation, acting downstream of factor XII. However, patients deficient in upstream members of the contact pathway, including FXII and prekallikrein, do not exhibit bleeding complications, while FXI-deficient patients sometimes experience mild bleeding, suggesting FXI plays a role in hemostasis independent of the contact pathway. Further complicating the picture, bleeding risk in FXI-deficient patients is difficult to predict because bleeding symptoms have not been found to correlate with FXI antigen levels or activity. However, recent studies have emerged to expand our understanding of FXI, demonstrating that activated FXI is able to activate coagulation factors FX, FV, and FVIII, and inhibit the anti-coagulant tissue factor pathway inhibitor (TFPI). Understanding these activities of FXI may help to better diagnose which FXI-deficient patients are at risk for bleeding. In contrast to its mild hemostatic activities, FXI is known to play a significant role in thrombosis, as it is a demonstrated independent risk factor for deep vein thrombosis, ischemic stroke, and myocardial infarction. Recent translational approaches have begun testing FXI as an antithrombotic, with one promising clinical study showing that an anti-sense oligonucleotide against FXI prevented venous thrombosis in elective knee surgery. A better understanding of the varied and complex role of FXI in both thrombosis and hemostasis will help to allow better prediction of bleeding risk in FXI-deficient patients and also informing the development of targeted agents to inhibit the thrombotic activities of FXI while preserving hemostasis.

AB - Coagulation factor (F)XI has been described as a component of the early phase of the contact pathway of blood coagulation, acting downstream of factor XII. However, patients deficient in upstream members of the contact pathway, including FXII and prekallikrein, do not exhibit bleeding complications, while FXI-deficient patients sometimes experience mild bleeding, suggesting FXI plays a role in hemostasis independent of the contact pathway. Further complicating the picture, bleeding risk in FXI-deficient patients is difficult to predict because bleeding symptoms have not been found to correlate with FXI antigen levels or activity. However, recent studies have emerged to expand our understanding of FXI, demonstrating that activated FXI is able to activate coagulation factors FX, FV, and FVIII, and inhibit the anti-coagulant tissue factor pathway inhibitor (TFPI). Understanding these activities of FXI may help to better diagnose which FXI-deficient patients are at risk for bleeding. In contrast to its mild hemostatic activities, FXI is known to play a significant role in thrombosis, as it is a demonstrated independent risk factor for deep vein thrombosis, ischemic stroke, and myocardial infarction. Recent translational approaches have begun testing FXI as an antithrombotic, with one promising clinical study showing that an anti-sense oligonucleotide against FXI prevented venous thrombosis in elective knee surgery. A better understanding of the varied and complex role of FXI in both thrombosis and hemostasis will help to allow better prediction of bleeding risk in FXI-deficient patients and also informing the development of targeted agents to inhibit the thrombotic activities of FXI while preserving hemostasis.

KW - bleeding

KW - coagulation factor XI

KW - coagulation factor XII

KW - contact activation pathway

KW - hemophilia C

KW - hemostasis

UR - http://www.scopus.com/inward/record.url?scp=84989855590&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84989855590&partnerID=8YFLogxK

U2 - 10.1016/S0049-3848(16)30354-1

DO - 10.1016/S0049-3848(16)30354-1

M3 - Article

C2 - 27207433

AN - SCOPUS:84989855590

VL - 141

SP - S8-S11

JO - Thrombosis Research

JF - Thrombosis Research

SN - 0049-3848

ER -